Anika Therapeutics (ANIK) Misses Q4 EPS by 10c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $14.20 --0%
Revenue Growth %: +3.5%
Financial Fact:
Selling, general & administrative: 4.28M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +3.5%
Financial Fact:
Selling, general & administrative: 4.28M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q4 EPS of ($0.34), $0.10 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $39.62 million versus the consensus estimate of $37.71 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- FirstCash to acquire UK pawn operator Ramsdens for £206 million
- Keurig Dr Pepper coffee chief to depart ahead of planned split
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
